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Role of Leukotriene Receptor Antagonists in AsthmaAsthma is a chronic inflammatory disease that affects >300
million people worldwide. However, inhaled corticosteroids
(ICS), the gold standard therapy for persistent asthma,
cannot suppress every component of airway inflammation
and often fail to adequately penetrate the small airways in
order completely suppress eosinophilia. Cysteinyl leukotri-
enes are important inflammatory factors that are involved
in asthma and allergic diseases, and montelukast, a cys-
teinyl leukotriene receptor antagonist (LTRA), is a compet-
itive antagonist of these substances for the cysteinyl
leukotriene type-1 receptor 1 (LTR1). Montelukast mono-
therapy has been shown to relieve the clinical symptoms of
mild persistent asthma. As either a monotherapy or in
combination with ICS, montelukast provides clinically
relevant improvements to various asthma-related parame-
ters, including symptoms, lung function, quality of life, and
asthma exacerbations, and has been found to reduce
eosinophilic airway inflammation by downregulating Mac-1
expression and eosinophil chemotaxis in patients with
chronic asthma.1,2 Furthermore, montelukast has been re-
ported to produce bronchoprotective effects against both
specific and nonspecific bronchoactive stimuli. When
treating childhood asthma, montelukast demonstrates
faster clinical responses than ketotifen, including improved
exhaled nitric oxide, peak expiratory flow, and asthma
scores within 1 week.3 Similarly, in patients with allergic
rhinitis, montelukast produces substantial improvements in
symptoms and quality of life.2 The anti-inflammatory
effects of LTRA have been reported widely in both in vivo
and in vitro studies.4 Several studies have reported that
LTRA may have anti-inflammatory effects, not only as an
antagonist to LTR1, but also as an inhibitor of inflammatory
cells. For example, montelukast and zafirlukast, two LTRAs,
significantly downregulate monocyte chemoattractant
protein-1 (MCP-1)-induced chemotaxis of human primary
monocytes via the downregulation of MCP-1-induced [Ca2þ]i
and p38 MAPK expression.5
Airway inflammation, hyperresponsiveness, and remod-
eling are the fundamental components of the subsequent
pathogenesis that leads to the symptoms and changes in1875-9572/$36 Copyright ª 2012, Taiwan Pediatric Association. Publish
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remodeling consists of the structural changes that occur in
the airways of the lungs as a result of asthma, and the
remodeling process involves diverse pathological changes
that include epithelial metaplasia, subepithelial fibrosis,
angiogenesis, and smooth muscle thickening. Airway
remodeling will result in the irreversible loss of lung func-
tion and airway hyperresponsiveness. Airway remodeling is
usually associated with severe and persistent disease with
poor control. Current asthma therapies (e.g., ICS) can
successfully treat allergic inflammation, an important
factor that contributes to remodeling, but these therapies
do not specifically target the remodeling processes that can
progress despite the optimal control of inflammation.
Moreover, airway remodeling might not be prevented
despite the widespread use of anti-inflammatory treat-
ments. There is limited evidence demonstrating the
effectiveness of leukotriene inhibitors for the treatment or
prevention of remodeling changes. The search for novel
therapies that can reverse or prevent airway remodeling is
a very active area in asthma research. Long-term studies on
the effects of LTRA on airway remodeling in human asthma
patients are still lacking and need to be performed.
A better understanding of airway remodeling in asthma
patients will facilitate the development of new treatments
for asthma that go beyond the control of symptoms and
inflammation. Treatments that may be useful for prevent-
ing airway remodeling include those that target single or
multiple components of the airway remodeling process.
Matrix metalloproteinase 9 (MMP-9) acts as a proin-
flammatory molecule that perpetuates immune responses,
but it is also involved in the repair processes that are
activated following tissue injury and may regulate remod-
eling during inflammatory reactions. MMP-9 is critically
involved in the recruitment of eosinophils and T-helper 2
(Th2) cells to the lungs following allergen challenges and
the subsequent development of Th2 responses to allergens.
Regarding this issue, Hsu et al presents the effects of
a selective LTRA (MK-679) on airway inflammation and MMP
expression in a mouse model.6 In a study on childhooded by Elsevier Taiwan LLC. All rights reserved.
220 Editorialasthma,7 patients on montelukast therapy for 8 weeks
demonstrated significantly decreased levels of exhaled
nitric oxide and plasma MMP-9 that were associated with
improved symptoms and enhanced peak expiratory flow but
not significantly associated with increased levels of tissue
inhibitor metalloproteinase-1 (TIMP-1). Montelukast also
demonstrates anti-inflammatory properties, including
reducing or preventing eosinophilia, which may be partially
due to reductions in MMP-97 because MMP-9 plays an
important role in both airway inflammation and remodel-
ing.8 LTRA has been shown to regulate MMP-9 expression in
both mouse and human studies. Therefore, some LTRAs may
demonstrate effects on the airway remodeling of asthma
in vitro. Large population and long-term human in vivo
studies are still needed to determine the effects of LTRA on
airway remodeling.Chih-Hsing Hung
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